dc.contributor.author | Rubbia-Brandt, Laura | |
dc.contributor.author | Lauwers, Gregory Y. | |
dc.contributor.author | Wang, Huamin | |
dc.contributor.author | Majno, Pietro E | |
dc.contributor.author | Tanabe, Kenneth Kenji | |
dc.contributor.author | X Zhu, Andrew | |
dc.contributor.author | Brezault, Catherine | |
dc.contributor.author | Soubrane, Olivier | |
dc.contributor.author | Abdalla, Eddie K | |
dc.contributor.author | Vauthey, Jean-Nicolas | |
dc.contributor.author | Mentha, Gilles | |
dc.contributor.author | Terris, Benoit | |
dc.date.accessioned | 2018-03-27T18:08:59Z | |
dc.date.issued | 2010 | |
dc.identifier.citation | Rubbia-Brandt, Laura, Gregory Y Lauwers, Huamin Wang, Pietro E Majno, Kenneth Tanabe, Andrew X Zhu, Catherine Brezault, et al. 2010. “Sinusoidal Obstruction Syndrome and Nodular Regenerative Hyperplasia Are Frequent Oxaliplatin-Associated Liver Lesions and Partially Prevented by Bevacizumab in Patients with Hepatic Colorectal Metastasis.” Histopathology 56 (4) (March): 430–439. doi:10.1111/j.1365-2559.2010.03511.x. | en_US |
dc.identifier.issn | 0309-0167 | en_US |
dc.identifier.uri | http://nrs.harvard.edu/urn-3:HUL.InstRepos:35140974 | |
dc.description.abstract | AIMS: Because of its efficacy, oxaliplatin (OX) is increasingly used as a chemotherapeutic agent in the treatment of colorectal liver metastases (CRLM). Oxaliplatin-associated liver toxicity has been reported and can affect clinical practice, but studies on its prevalence and a full pathological description are lacking. The aims of this study were to fill this gap by providing, from a pathologist's perspective, a detailed assessment of the spectrum of hepatic lesions associated with OX, to suggest a scoring system to quantify them, and to investigate the protective effect of bevacizumab against OX-associated damage. METHODS AND RESULTS: The spectrum of oxaliplatin-associated liver lesions was investigated in a multi-institutional series of surgically resected CRLM (n = 385). Among 274 patients treated by OX, 54% had moderate/severe sinusoidal obstruction syndrome (SOS). Peliosis, centrilobular perisinusoidal/venular fibrosis and nodular regenerative hyperplasia (NRH) developed in 10.6%, 47% and 24.5%, respectively. The 111 patients treated by surgery alone had no lesions. Hepatic lesions were less severe in patients treated with OX/bevacizumab (n = 70) compared with the group treated by OX alone (n = 204), with an incidence of moderate/severe SOS (31.4% versus 62.2%), peliosis (4.3% versus 14.6%), NRH (11.4% versus 28.9%, respectively) and centrilobular/venular fibrosis (31.4% versus 52%, respectively) (P < 0.001). CONCLUSIONS: Pathologists should be aware of the distinctive lesions associated with OX and of their high prevalence. OX-related lesions are less frequent in patients treated with bevacizumab, suggesting that this drug has a preventive effect. Uniform criteria for diagnosis and grading of OX-associated lesions should help to include histological data in the optimal multidisciplinary management of CRLM. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | Wiley-Blackwell | en_US |
dc.relation.isversionof | doi:10.1111/j.1365-2559.2010.03511.x | en_US |
dash.license | META_ONLY | |
dc.title | Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis | en_US |
dc.type | Journal Article | en_US |
dc.description.version | Version of Record | en_US |
dc.relation.journal | Histopathology | en_US |
dash.depositing.author | Lauwers, Gregory Y. | |
dash.embargo.until | 10000-01-01 | |
dc.identifier.doi | 10.1111/j.1365-2559.2010.03511.x | * |
dash.authorsordered | false | |
dash.contributor.affiliated | Tanabe, Kenneth | |
dash.contributor.affiliated | Lauwers, Gregory Y. | |